Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Mette Thune MouritzenMorten LadekarlHenrik HagerTrine Block MattesenJulie B LippertMalene Støchkel FrankAnne K NøhrIda B EgendalAndreas CarusPublished in: Cancers (2023)
/L and absence of liver metastases were significantly associated with DCB in ICI-treated patients with NSCLC. GEP was only feasible in 20% of the patients. GEP-derived signatures may be associated with clinical outcomes, and PD-L1 could be assessed by GEP rather than IHC.
Keyphrases
- advanced non small cell lung cancer
- liver metastases
- newly diagnosed
- end stage renal disease
- epidermal growth factor receptor
- small cell lung cancer
- chronic kidney disease
- peripheral blood
- peritoneal dialysis
- prognostic factors
- gene expression
- copy number
- patient reported outcomes
- tyrosine kinase
- transcription factor